Mounjaro’s Cardiovascular Approval: Who the New Indication Covers

Mounjaro’s U.S. prescribing information now includes a cardiovascular indication: reducing major cardiovascular events in adults with type 2 diabetes who are at high risk for those events. The label, revised in August 2026, specifies cardiovascular death, nonfatal heart attack or nonfatal stroke.¹

This is a specific approved use. It is not a blanket “heart protection” approval for everyone taking tirzepatide, and it is not the same as approval to treat heart failure. Zepbound contains the same active drug but has its own indications.

Who the indication covers

The cardiovascular indication is for adults with type 2 diabetes at high cardiovascular risk. A person without type 2 diabetes should not assume the new wording applies simply because they have obesity, a family history of heart disease or a prescription for Zepbound.¹

Ask the treating clinician how your medical history relates to the indication and which outcomes the treatment is intended to address. The label wording does not replace an assessment of the rest of your cardiovascular care or make other prescribed therapies unnecessary.

What the cardiovascular trial established

The label summarizes SURPASS-CVOT, comparing Mounjaro with dulaglutide in adults with type 2 diabetes and established cardiovascular disease. Mounjaro met the trial’s noninferiority criterion for the three-event cardiovascular composite; superiority over dulaglutide was not established. The reported hazard ratio was 0.92, with a 95.3% confidence interval of 0.83–1.01.¹

That distinction prevents an important misreading: a new indication does not mean the trial proved Mounjaro was better than every other treatment. Compare the actual comparator, outcome and statistical conclusion rather than treating a relative number as a universal ranking.

Is Zepbound now approved for the same thing?

No. Zepbound’s current U.S. label lists weight reduction and long-term maintenance in eligible adults, and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. It does not list the Mounjaro cardiovascular indication.²

Our Mounjaro versus Zepbound guide explains why the same molecule can have different brand labeling. Do not change brands, combine products or change dosing on the strength of a headline. A prescription and coverage decision must match the patient, indication and actual product.

Is this a heart-failure approval?

Major cardiovascular events and worsening heart-failure events are different endpoints. The Mounjaro indication should not be renamed a general heart-failure indication. The separate SUMMIT evidence in obesity-related heart failure with preserved ejection fraction is explained in our HFpEF guide.

When reading a study, check whether its composite includes cardiovascular death, heart attack, stroke, hospitalization or a worsening-heart-failure event. Two headlines can both say “heart benefit” while describing different patient populations and different outcomes.

Does approval guarantee insurance coverage?

An approved indication does not establish your plan’s formulary, prior-authorization criteria or copayment. Ask the pharmacy-benefit administrator about the exact prescription and indication, and ask the clinician what documentation is required. Our insurance guide explains why a formulary listing and a benefit approval are separate steps.

Avoid substituting a promotional cash price for a verified insurance cost. The relevant comparison includes your actual product, ongoing dose, medication charge and any separate professional fees.

What to ask at your next visit

Ask what the new indication changes for your own treatment goals, if anything. Discuss how it fits with diabetes management, blood pressure, cholesterol treatment and other medication decisions. Keep the difference between an approved use and an individual recommendation clear.

For a broader view of the molecule, start with the tirzepatide evidence guide. For a developing research result, look for its trial design and population before assuming it has changed the label. Here, the decisive source is the current prescribing information itself.